COX-2 inhibitors and cardiovascular risk

July 2003    Volume 10, Issue 4   Br J Cardiol 2003;10:288-92

Authors:
COX-2 inhibitors and cardiovascular risk Mike Schachter

Non-steroidal anti-inflammatory drugs (NSAIDs) have potentially dangerous side effects, which has led to intense interest in the development of the cyclo-oxygenase (COX) inhibitors. This article reviews the science, safety and clinical evidence to date with these drugs.
They appear to have fewer gastrointestinal and equivalent renal risks to NSAIDs. Reviewing the clinical evidence, particularly the complex cardiovascular effects of the COX inhibitors, the article discusses the clinical relevance of their thrombogenic and anti-atherosclerotic potential. Since many of the studies are retrospective analyses, randomised clinical trials are needed to ascertain whether these cardiovascular effects constitute a problem or an unexpected benefit, and whether there are differences between the different COX-2 inhibitors.

back to top

Comments

There are currently no comments for this article - leave a comment

You must be logged in to post a comment.
Not yet a member? Register now for free.

back to top